Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits... see more

Current News (NDAQ:ANAB)

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

GlobeNewswire 8 days ago

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 10 days ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

PR Newswire December 15, 2025

Anaptys Announces Participation in December Investor Conferences

GlobeNewswire November 25, 2025

Anaptys Announces $100 Million Stock Repurchase Plan

GlobeNewswire November 21, 2025

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GlobeNewswire November 21, 2025

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

GlobeNewswire November 10, 2025

Anaptys Announces Participation in November Investor Conferences

GlobeNewswire November 4, 2025

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 4, 2025
View More News ››

Opinion & Analysis (NDAQ:ANAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ANAB)

5 PROMISING STOCKS IN ALOPECIA AREATA

5 PROMISING STOCKS IN ALOPECIA AREATA   1 In 5 Americans Are Losing Their Hair... More than 50 percent of women experience...
AviseAnalytics - July 7, 2021
View more Bullboard ››

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc. engages in the acquisition, exploration, and development of mineral properties in North ...
View More »

Podcasts